Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vital Farms Inc (VITL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vital Farms Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Vital Farms Inc trades at $12.44 (market cap $563.24M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 8× Vital Farms Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | VITL | |
|---|---|---|
Market Cap | $4.49B | $563.24M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $52.41 |
52-Week Low | $20.06 | $8.28 |
Enterprise Value | $3.69B | $566.05M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Vital Farms (VITL) trades at $12.84, up 0.63% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported 2025 revenue of $759.44M and net income of $66.28M, though earnings have missed expectations in recent quarters. Analysts maintain a Buy consensus with a $14.00 price target, but negative cash flow and a class action lawsuit pose headwinds.
The stock offers value with a P/E of 12.35 and P/S of 0.75, but risks include declining profitability, legal challenges, and sustained negative cash flow. Upside depends on execution improvements and resolving litigation, while failure to stabilize earnings could pressure valuations further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
